| obesity and overweight | versus placebo or control No demonstrated result for efficacy | 6 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Bray, 2003 | Topiramate vs placebo | | | | | Caterson, 2003 | Topiramate vs placebo | | | | | Pud’homme, 2003 | Topiramate vs placebo | | | | | Rissanen, 2003 | Topiramate vs placebo | | | | | Stenlof, 2003 | Topiramate vs placebo | | | | | Tonstad, 2003 | Topiramate vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Bray, 2003 | (n=75) vs. (n=75) | | Sample size: 75/75 Primary endpoint: FU duration: | | Caterson, 2003 | (n=93) vs. (n=97) | | Sample size: 93/97 Primary endpoint: FU duration: | | Pud’homme, 2003 | (n=33) vs. (n=33) | | Sample size: 33/33 Primary endpoint: FU duration: | | Rissanen, 2003 | (n=123) vs. (n=103) | | Sample size: 123/103 Primary endpoint: FU duration: | | Stenlof, 2003 | (n=135) vs. (n=137) | | Sample size: 135/137 Primary endpoint: FU duration: | | Tonstad, 2003 | (n=178) vs. (n=177) | | Sample size: 178/177 Primary endpoint: FU duration: |
|
